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2,3-Dihydropyridin-4(1H)-ones were utilized as scaffolds for the syntheses of
libraries of 5-arylethynyl-2,3-dihydropyridin-4(1H)-ones and 2-(3-formyl-5-
arylfuran-2-yl)ethylcarbamates. 2,3-Dihydropyridin-4(1H)-ones were prepared from
piperidones, ynones, and pyridones and used for the synthesis of a library of 5-
arylethynyl-2,3-dihydropyridin-4(1H)-ones employing a Sonogashira coupling
reaction.  Further reaction of these compounds using an Au(III)-catalyzed cyclization
method yielded formylfurans.
N-Boc and N-benzyl protected 2,3-dihydropyridin-4(1H)-ones were prepared
for the Sonogashira coupling reaction. N-Boc-protected 5-iodo-2,3-dihydropyridin-
4(1H )-ones provided tert-butyl 5-arylethynyl-4-oxo-3,4-dihydropyridine-1(2H)-
carboxylates  in moderate to excellent yields while the N-Bn-protected enaminones
provided very low yields of 5-arylethynyl-1-benzyl-2,3-dihydropyridin-4(1H)-ones.
Furan formation was achieved by Au(III)-catalyzed and Cu-mediated
cyclizations. tert-Butyl 1-(3-formyl-5-phenylfuran-2-yl)propan-2-ylcarbamates  were
iii
obtained during the Sonogashira coupling reactions catalyzed by Cu(I), while tert-
Butyl 1-(3-formyl-5-phenylfuran-2-yl)-3-phenylpropan-2-ylcarbamates were formed
by the Au(III)-catalyzed cyclization. Some of the furans were obtained by both
methods. Only in the case of tert-butyl 4-methoxy-2-p-tolyl-6,7-dihydrofuro[3,2-
c]pyridine-5(4H)-carboxylate was the –OMe group retained under Au(III)-catalyzed
cyclization conditions, which involved methanol as a nucleophile. In all other cases,
N-Boc 3-formyl furans were formed. A library of 16 compounds of functionalized
furans possessing the N-Boc adehyde functionality was constructed in moderate to
excellent yields.
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1Chapter 1. Introduction
1.1 Background of Enaminone Chemistry
Enaminones, indicating any compound with the conjugated system N−C=
C−C=O shown in Figure 1, have been known for many years.1, 2
R1
O
NR24
R3
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Figure 1. A symbolized structure of enaminones.
There are various synthetic methods of enaminone formation such as addition
reactions, cleavage of heterocycles, acylations of enamines and so on.2 Eq.1 (Scheme
1) is shown an example of enaminone formation by a condensation reaction.
Dimedone 1a reacts with ammonia under refluxing condition to provide enaminone
1b. Eq.2 of Scheme 1 is an example of an addition reaction.  Benzylmagnesium
chloride was added to nitrile 2a to form enaminone 2b in a very good yield.3 The
reduction of isoxazole derivatives has also been studied toward enaminone formation,
shown in Eq. 3 (Scheme 1). A classical reduction method is applied in Eq. 3 to cleave
the isoxazole ring of 3a using hydrogen with PtO2 or Raney Ni to give 78 and 100%
yield of enaminone 3b, respectively.4, 5 Eq. 4 (Scheme 1) shows an example of
acylation of  an enamine.6 Acid chloride 4a reacts with enamine 4b in the presence of
Et3N to give tricyclic pryridone 4c  in 92% yield. Furthermore, there are many
examples of enaminone formations reported using condensation reactions.1, 7, 8
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Scheme 1. Enaminone formations from various reactions; Eq.18: condensation
reaction, Eq.23: addition reaction, Eq. 34, 5 cleavage of heterocycles, and
Eq. 46: acylation of enamines.
In 1972, Foowler9 published a useful method for enaminone formation by the
reduction of pyridines with sodium borohydride in the presence of alkyl
chloroformate resulting in 2-unsubstitued 1-(alkoxycarbonyl)-1,2-dihydropyridines 2
via 1-acylpyridinium salt 1 (Scheme 2). These heterocyclic compounds are
particularly useful for the syntheses of various alkaloids and novel ring systems.
Applications of these heterocycles for the Diels-Alder and other reactions have been
investigated by several research groups.10-13
3In 1970, prior to Foowler’s report, Fraenkel and co-workers reported that 4-
picoline reacted with Grignard reagents in the presence of ethyl chloroformate to give
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Scheme 2. Cyclic enaminone formation.
2-substituted 1-(ethoxycarbonyl)-1,2-dihydropyridines 3.14 These substituted 1,2-
dihydropyridines 3 and 2,3-dihydro-4-pyridones 4 were prepared by the addition of
nucleophiles to 1-acylpyridinium salts 1 and were utilized as  building blocks for the
syntheses of natural products. The C2 substitutents of 3 and 4 are in a pseudoaxial
orientation due to A(1,3) strain,15 providing a conformational restriction in the
molecules. This effect results in high facial selectivity in the Diels-Alder reaction of
3.16, 17 Similarly, the reaction with molecule 4 shows stereoselectivity as a result of
conformational preference of 4 for 1,2- and 1,4- additions18-20 to the enone moiety, C3
alkylation,21-23 Luche reduction of the C4 carbonyl,18-20, 24 and intramolecular radical
cyclization.25 Furthermore, Comins and his co-workers have studied extensively the
4addition of Grignard reagents to 1-acylpyridinium salts and developed the syntheses
and synthetic applications of heterocycles 3 and 4 since 1982.26 Since the piperidine
moiety are found in many natural products, Comins and co-workers utilized 3 and 4
as synthetic intermediates for the preparation of various natural products, such as
piperidine, indolizidine, quinolizidine, and cis-/trans-decahydroquinoline alkaloids.27,
28
1.2 Current Study
Syntheses of natural products are challenging subjects to organic and medicinal
chemists. Although many natural products are biologically active, their isolated yields
from natural resources are often too low for extensive studies of their properties.
Many natural products, however, have common moieties such as pyrroles,
indolizidines, quinolizidines, perhydroindoles, and piperidine.27, 29 The development
of new synthetic methodology of these heterocycles will provide better access to
these structures to medicinal chemists. As mentioned earlier, since the piperidine
moiety is quite common in many natural products, especially in alkaloids, the
preparation of these alkaloids through cyclic enaminone intermediates is well known
in the literature.27, 29-33
Cyclic enaminones provide the scaffolds for annulations toward systems such as
pyrroles, indolizidines, quinolizidines, and perhydroindoles.2, 27, 29, 34 Figure 2 shows
5N
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6
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enolate
alkylation
5
Figure 2. Synthetic utilities of N-acyldihydropyridones 5.35
the synthetic utility of cyclic enaminones.  Cyclic enaminone, 2,3-dihydropyridin-4-
one, has a simple “enone” structure acting as a Michael acceptor in conjugate
additions.34 Substituents at C436 and C619, 20, 24 can be installed via 1,2 additions and
1,4-conjugate additions, respectively.35
For example, 1,2-addition at C4 was achieved by using a cerium-mediated
addition of an alkyllithium to 5 to afford allylic tertiary alcohols.36 Enolate alkylation
at C322, 37 was carried out in the presence of LiHMDS/MeI to afford trans-2,3-
dialkyl-2,3-dihydropyridin-4-one in 87% yield.21 Electrophilic substitution at C5 was
also reported by Comins and co-workers.35 They preformed the iodination at C5 of 5
in the presence of NIS and a catalytic amount of [hydroxy(tosyloxy)-
iodo]benzene(HTIB) followed by a palladium-catalyzed cross-coupling reaction to
give 5-iodo-2,3-dihydropyridin-4-one in high yield.
Recently, our group started investigating the cyclic enaminone formation
through amino-ynone intermediates (Scheme 3).38 The formation of enaminone 8 was
initiated from N-Boc-homopipecolic acid, followed by Weinreb amide formation and
the addition of ethynylmagnesium bromide to provide ynone 7.  Subsequent amine
deprotection and cyclization furnished 8 in excellent yield.
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MgBr2)
81% (2 steps) 87- 95%6 7 8
Scheme 3. Enaminone formation from β–amino acid.
1.3 The Purpose of the Research
Highly substituted furans are molecular fragments present in many biologically
active natural products, as shown in Figure 3.39, 40 In 2004, Larock and co-workers
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Figure 3. Furan containing natural products.
published an efficient method to synthesize highly functionalized furans from 2-(1-
alkynyl)-2-alken-1-ones (Scheme 4) using Au(III) as a catalyst.41 They installed the
alkynyl group on the C2 position in the cyclohexenone system via a Sonogarshira
coupling reaction, and then the β–ynone 9 reacted with the AuCl3 catalyst in the
7presence of nucleophiles to afford highly functionalized furans 10. Larock’s
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9 10
Scheme 4. The Au(III)-catalyzed cyclization toward functionalized furans.41
methodology inspired us to explore the utility of enaminones toward furans synthesis
as shown in Scheme 5. The furan moiety is very attractive in drug discovery since
many natural products that contain the furan moiety are biologically active.42
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MeOH, CH2Cl2
R= H, Me, Ph, and Bn
R'= H, Me, OMe, and Cl
Scheme 5. The utilization of enaminones toward the synthesis of furans using AuCl3
as a catalyst.
We hypothesized that arylalkynyl groups can be installed at C5 of our
enaminone systems by a Sonogashira coupling reaction and that the products can be
converted to functionalized furans in the presence of an Au(III) catalyst. Ultimately,
this strategy can be extended to construct libraries of alkynyl-enaminones as well as
functionalized furans in a combinatorial parallel synthesis fashion.
8Chapter 2. Chemistry and Results
2.1 The Syntheses of 2-Alkyl-5-iodo-2,3-dihydropyridin-4-ones
Scheme 6 shows the initial attempt to prepare a key intermediate towards the
synthesis of 2-ethynyl-2,3-dihydropyridin-4-one.  We attempted to generate the
desired 2-benzyl-2,3-dihydropyridin-4-one (14)38 and then performed α–halogenation
at C5 of 14. Amide 12 was generated by reacting HN(OMe)Me with EDCI and
commercially available N-Boc protected homo-phenylalanine (11). Ynone 13 was
prepared by adding ethynyl magnesium bromide to 12. After Boc deprotection 2-
benzyl-2,3-dihydropyridin-4-one (14) was obtained. Compound 14 was halogenated
at C5 with I2 and Et3N at room temperature to afford 2-benzyl-5-iodo-2,3-
dihydropyridin-4(1H)-one (15) in 94% yield.
HN(OMe)Me•HCl
THF, 0 °C
94% 95%
NMM, EDCI
DCM, 0 °C
MgBr
1) HCl/ Dioxane
2) MeOH, K2CO3
83%
94%
I2, Et3N
DCM, rt., 2 h
11 12 13
1415
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H
HN
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I
Ph
H
HN
OPh
H
Ph OH
ONHBoc
H
Ph N
ONHBoc
H
OMe Ph
ONHBoc
H
16
Scheme 6. The synthesis of (S)-2-benzyl-5-iodo-2,3-dihydropyridin-4(1H)-one (15 )
from (S)-N-Boc-β-phenylalanine (11).
9However, the installation of an aryl-ethynyl group at C5 of enaminone 15 using
the Sonogashira reaction was not successful. Presumably the free nitrogen was a
poison to the Pd (II) catalyst and C5 was not electrophilic enough toward Pd (0). We,
therefore, synthesized additional enaminones (Scheme 7) to further examine this
reaction. As shown in Scheme 7, enaminones can be prepared from three different
starting materials, such as piperidones, ynones, and pyridone. Starting with
piperidones or pyridone shortened our synthetic procedures toward the preparation of
enaminones. Enaminone analogues can be obtained in one step synthetic procedures
by  oxidation of piperidones or conjugate additon to pyridones. N-Bn-protected
enaminones can be synthesized from β–amino acid via an amino-ynone intermediate.
N
R2
O
R1
R3 R
1= Me, Ph, Bn
R2 = Bn, Boc
R3= Arylethynl
N
H
O
N
O
R2
BocN
O
Bn
Scheme 7. Retro-synthetic routes for enaminone formations.
We prepared two different intermediates, the N-Bn-protected iodoenaminone 21
(Scheme 8) and N-Boc-protected iodoenaminone 22 (Scheme 9), for the coupling
reaction. As shown in the Scheme 8, N-Boc-β-alanine was reacted with HN(OMe)Me
10
and EDCI to provide amide 17. Subsequently Bn-protection of the amine was
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Scheme 8. The preparation of N-Bn-5-iodo-2,3-dihydropyridin-4-one from N-Boc-
Alanine.
performed to afford amide 18 and ynone 19 was prepared by the addition of
ethynylmagnesium bromide. After amine deprotection and cyclization, ynone 19 was
converted to cyclic enaminone 20. Enaminone 21 was prepared by iodination of
enaminone 20. The synthesis of N-Boc-protected enaminone, however, was carried
N
O
Boc
N
O
Boc
IBX, MPO
DMSO, rt, 3d
I2 , K2CO3
DMF, overnight
56% / 2 steps
N
O
Boc
I
22
Scheme 9. The synthesis of N-Boc-5-iodo-enaminone from N-Boc-piperidone.
out by oxidation of N-Boc-piperidone (Scheme 9). As shown in Scheme 9, we started
from commercially available N-Boc-protected piperidone. The piperidone was treated
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with freshly prepared IBX with 4-methoxypyridine-N-oxide (MPO) in DMSO at
room temperature to afford the desired enaminone.43, 44 Iodination of the enaminone
provided us with a good yield of intermediate 22.
N
H
O
N
O
Boc
Boc2O, NaH
t-BuOH, 50 °C→ r.t.
77%-96%
23 (42 g)
N
O
Boc
R1
R1MgX
TMSCl
THF, -78 °C
R1= 24a: Me
       24b: Ph
       24c: Bn
N
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CH2Cl2, r.t.
47%-99%37%-99%
R1= 25a: Me
       25b: Ph
       25c: Bn
Scheme 10. The synthesis of N-Boc-5-iodo-enaminone from pyridone.
Additionally, N-Boc-protected iodo-enaminones 25 were prepared from
pyridone.  Commercially available pyridone was treated with Boc-anhydride and
NaH in t-BuOH at 50 °C to give N-Boc-pyridone 23 in moderate to excellent yields.45
Pyridone 23 was used to obtain three different enaminone scaffolds 24 upon reactions
with three different Grignard reagents in the presence of TMSCl in THF at -78 °C.
Then, iodo-enaminones 25a-25c were prepared using NIS in DCM for the library of
2-alkyl-5-arylethynyl-2,3-dihydropyridin-4-ones (Scheme 10).46
2.2 The Syntheses of 5-Arylethynyl-2,3-dihydropyridin-4-ones
From the initial failure of the aryl-ethynyl-enaminone synthesis, it was suspected that
the cause of failure in the Sonogashira reaction might be the poor electrophilicity at
C5 and the free nitrogen. To investigate these hypotheses, we prepared two different
precursors for the coupling reaction, N-Bn-enaminone 21 and N-Boc-enaminone 22.
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In order to install the aryl-ethynyl moiety at C5, we tried not only the Sonogashira
reaction41 but also other coupling reactions, such as Suzuki,47 Negishi,48 Castro-
Stephens,49 and Suzuki-Miyaura coupling reactions (Scheme 11).50 Preliminary
studies had been carried out on enaminone 15 for the Sonogashira reaction, using a
series of bases at various reaction temperatures before we carried out the coupling
Table 1. Initial results of cross-coupling reaction with iodoenaminone 15
Base        Solvent     Temp.( °C)    Time (h)            Product
aDIPA       THF          0→ r.t.             24            Dehalogenated 14
aEt3N         DMF         r.t.                   24             Dehalogenated 14
aEt3N         DMF         45                   24              a dimer of 14
bK2CO3      DMF        110                  27             Decomposition of 15
a: Sonogashira coupling reaction (Pd(PPh3)4, CuI, and 4-methoxy-1-ethynyl
    benzene were used additionally.)
b: Castro-Stephens coupling reaction (CuI and PPh3 were used additionally.)
reaction of enaminone 21 and 22. Table 1 is shown the initial results of cross-
coupling reaction with iodoenaminone 15. DIPA in THF (0 °C to room temperature
overnight) and Et3N in DMF at room temperature provided the dehalogenated
enaminone 14.  Reaction at 45 °C for 24 h produced the dimer of 14. The Catro-
Stephens coupling reaction49 was also carried out at 110 °C in DMF for 27 h and
decompositon of enaminone 15 was observed.  In additon, Suzuki coupling reaction47
of enaminone 15 with a different coupling partner, 4-methoxy-phenyl boronic acid,
provided the same dehalogenated enaminone 14 and unreacted starting material. The
free nitrogen and the poor elecrophilicity of 15 were problematic for the coupling
13
reaction. Therefore, iodoenaminones 21 and 22 were expected to perform better in the
coupling reaction.
A Negishi coupling reaction48 was the first attempt of a coupling reaction with
enaminone 21 but only dehalogenated enaminone 20 and starting material 21 were
observed. From the results of the Negishi coupling reaction, it appeared that the cause
of failure in the coupling reaction was due to the poor eletrophilicity of enaminone
21. We, therefore, performed a Suzuki-Miyaura coupling reaction of enaminone 21
(Scheme 11). Only trace amounts of our desired product 21a were observed. Also the
double addition product 21b and dehalogenated enaminone 20 were obtained. We
found a very weak signal of 21a by mass spectroscopy while the 1H NMR showed
21b as the major product.
N
O
Bn
I
BF3KMeO
Pd(OAc)2
N
O
Bn
OMe
MeO
N
O
Bn
OMe
+
Cs2CO3,S-Phos
MeOH, 50 °C
21 21a 21b
+
17% a
Scheme 11. Suzuki-Miyaura coupling reaction with N-Bn-iodo-enaminone.50a: The
yield is a mixture of 21a and 21b.
From the Suzuki-Miyaura coupling reaction, we observed the production of the
major by-product 21b, as shown in Scheme 11.   Arylenynes, such as 21b, have been
observed by Pal and co-workers during their studies of the palladium-catalyzed
reaction of 3-iodothioflavone with a terminal alkyne.51 It is known that Cu(I) acts as a
co-catalyst in Sonogashira reactions to activate terminal alkynes to form a Cu-
14
acetylide. The Cu-acetylide undergoes transmetallation with the arylpalladium halide
to generate the alkynylpalladium and subsequent reductive elimination gives the final
product.51, 52 Therefore, Pal and co-workers carried out the Sonogashira coupling
N
Bn
OPdCl2(PPh3)2, CuI
Et3N
DMF, rt.N
O
Bn
I
21
N
O
Bn
30a
+
30
Scheme 12. Sonogashira coupling reaction with N-Bn-iodo-enaminone 21.51
Table 2. Optimization of Sonogashira reaction with iodo-enaminone 21.
a: Pd(PPh3)4 was used instead of PdCl2(PPh3)2,b: 4 eqiv. of (S)-prolinol was used
      instead of Et3N.53
reaction under Cu-free conditions and observed an increased yield in the desired
product. Additionally, they performed the reaction using lesser amounts of alkynes
(M) (eq) (eq) ratio h oC 30 30a 21
0.01 0.04 0.05 1.25 20 rt >6% 23% <7%
0.01 0.04 0.4 10 96 rt 10% 0% 50%
0.1 0.05 0.25 5 3 rt 50% 11% 0%
a,  0.1 0.05 0.5 10 19 rt 18% trace trace
b,  0.1 0.05 0.5 10 21 rt 11% trace trace
0.1 0.05 0.5 10 48 0->rt Lost trace 0%
0.1 0.1 0.5 5 21 0->rt 18% 5% 0%
0.1 0.1 1 10 18 0->rt trace trace 0%
0.1 0.1 1 10 10 0 >16% trace 0%
YieldTime  TempConc.  Pd Cu  Cu/Pd
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and found that the generation of the double addition product was not dependent on the
quantity of alkynes used but possibly was due to the use of Cu as a co-catalyst. These
observations were consistent with our findings from the experiments of the Suzuki-
Miyaura coupling reaction as well as the Songashira reaction with iodo-enaminone
21. We did not observe the bis-addition by-product, seen in the Suzuki-Miyaura
coupling reaction, as shown in Scheme 11. The same reaction conditions were
applied to N-Bn-5-iodo-dihydropyridin- 4-one (21). We subsequently optimized the
reaction conditions, as shown in Scheme 12 and Table 2. We carried out a series of
Sonogashira coupling reactions with various amounts of CuI, as shown in Table 2. In
Table 2, the yield of our desired product 30 increased while the amount of 30a
decreased as the ratio of Cu to Pd increased. The results indicated that the Cu catalyst
played a critical role in suppressing the formation of 30a, although the precise role of
the Cu catalyst is unknown. We, however, did not observe the bis-addition by-product
formation in the Sonogashira reaction of N-Boc-protected enaminones 25a-25c, while
N-Bn-protected enaminone 21 was converted to 30  and 31a in very low yield.
Therefore, the amount of CuI we used was a key element to control for the
Sonogashira reaction of enaminone 21 in order to prevent forming 30a.
N
Boc
OPdCl2(PPh3)2, CuI
Et3N
DMF, rt.
 86%
N
O
Boc
I
22 26a
Scheme 13. Sonogashira coupling reaction with N-Boc-iodo-enaminone.51
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N-Boc-2,3-dihydropyridin-4-one (22) transformed smoothly to the coupled
product 26a in 86%, as shown in Scheme 13.51 Since the Sonogashira coupling
Table 3. The syntheses of 2-arylethynyl-enaminone by Sonogashira reaction.
N
O
Boc
N
O
Boc
R3 26:     H                       tracea
26a:   Me                     86
26b:   OMe                  64       
26c:   Cl                      tracea
27:    H                         60b
27a:  Me                       53
27b:  OMe                    70
27c:  Cl                         64
R3
N
O
Boc
Ph
28:     H                       86
28a:   Me                     98
28b:   OMe                  86
28c:   Cl                       86
R3
N
O
Boc
Bn
29:    H                         92
29a:  Me                       98
29b:  OMe                    94
29c:   Cl                        93
R3
Product R3 Yield(%)
N
O
Boc
R1
I R
3
PdCl2(PPh3)2
CuI, Et3N
DMF, r.t. N
O
Boc
R3
R1
R3 = H, Me, OMe, Cl
53%-99%
R1=  H, Me, Ph, Bn
a:Compound 26 and 26c were observed (1H NMR spectra) but the functionalized
furans 31a and 31d were isolated.
b: The yield is based on 1H NMR (2:1 ratio of compound 27 to furan 32a).
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reaction was successful in the case of N-Boc-5-iodo-2,3-dihydropyridin-4-one (22),
we decided to build a library of 2-alkyl-5-arylethynyl-2,3-dihydropyridin-4-ones.
Table 3 shows the library of 14 compounds prepared by the Sonogashira coupling
reaction in moderate to excellent yield. The optimized conditions, as shown in Table
2, were successfully applied to enaminones 25b and 25c. These enaminones were
converted to compounds 28-29c in 86-98% yield, while enaminone 22 and 25a
provided 5-arylethynyl-2,3-dihydropyridin-4-one as well as the corresponding
functionalized furans, depending on the alkynyl and enaminone substrates.
Therefore, enaminone scaffold 24 provided excellent opportunities for the
synthesis of a library of 2-alkyl-5-arylethynyl-2,3-dihydropyridin-4-one with various
reactivities among enaminones 21, 22, and 25a-25c in the Sonogashira reaction.
2.3 The Syntheses of Functionalized Furans
In 2004, Larock and co-workers published the Au(III)-catalyzed cyclization of
2-(1-alkynyl)-2-alken-1-ones to generate highly substituted furans.41 This
methodology was successfully applied to the enaminone system 26a. The synthesis of
N
Boc
O
N
O
OMe
Boc
AuCl3/MeCN
MeOH, CH2Cl2, 
rt.,
26a 31
68%
Scheme 14. The synthesis of tetrahydrofuropyridines by AuCl3-catalyzed cyclization.
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NH
OR1
Boc
O
R3
R3 = H, Me, OMe, Cl
N
O
Boc
R3
R1
AuCl3/MeCN
MeOH, CH2Cl2
R1= H, Me, Ph, Bn
Scheme 15. Au(III)-catalyzed cyclization of ynones and demethylation of
functionalized furans.
functionalized furans was established using Au(III)-catalyzed cyclization, as shown in
Scheme 14 and Table 4. However, an unexpected result was found during the
cyclization using the Au catalyst. The cyclization, as shown in Scheme 14, was the
only case in which the -OMe group at C4 was retained. With precursors 26b-29c
(Scheme 15 and Table 4) the corresponding aldehyde analogues were obtained.
Additionally, we observed formyl furans as by-products of the Sonogashira coupling
reactions of enaminone 22 and 25a, as shown in Scheme 16. Compounds 26 and 26c
were converted to furans directly during the coupling reaction.
N
Boc
OPdCl2(PPh3)2
CuI, Et3N
DMF, rt.
 86%
(2:1 ratio)
N
O
Boc
I
25a 27a
NH
O
Boc
O
32a
Scheme 16. Furan formation during the Sonogashira coupling reaction.
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Table 4. Au(III)-catalyzed cyclization of ynones and formyl functionalized furans.
NH
O
O
Boc
NH
O
R3
O
Boc
NH
O
R3
O
Boc
Ph
NH
O
R3
O
Boc
Bn
R3
         R3              Method         Yield (%)
31a:  H                      B              67   
31b:  Me                   A             trace    
31c:  OMe                 B              60
31d:  Cl                     B              57
32  :  H                      B              15a
32a:  Me                    B             74
32b:  OMe                 B             70
32c:  Cl                      B             40
33  :  H                       A (B)      23 (38 )a
33a:  Me                     A            48 
33b:  OMe                  A            77     
33c:  Cl                       A            36      
34  :  H                       A (B)      63 (89)
34a:  Me                     A            71
34b:  OMe                  A            77
34c:  Cl                       A            43
Method A : Au(III)-catalyzed cyclization, Method B : Cu(I)-catalyzed cyclization
a : based on 1H NMR
Product
Schemes 15 and 16 show the methods for furan synthesis using Au(III) and
Cu(I). Both schemes are showing that aldehydes were formed, instead of the methoxy
derivatives. Initially, it was believed that Au(III) might be involved in the elimination
of the methoxy group. Because the reaction took more than 2 h go to completion, we
explored a shorter reaction time (less than 1 h). Even the reduced reaction time
provided the 3-formyl furan. Additionally, when furan 31 was treated with the Au(III)
catalyst in MeCN, conversion to the 3-formyl furan took place. Scheme 17 shows the
proposed pathways for the cleavage of the bicyclic intermediate 30a to provide furans
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31a-34c. We believe that the Au(III)-catalyzed cyclization provides bicyclic
intermediate 30, which is hydrolyzed under acidic conditions to form an aldehyde
(Path A, Scheme 17). We observed aldehyde formation on a TLC plate, indicating
that the bicyclic system was very sensitive to acid. 1H and 13C NMR data showed
signals at 9.5 ppm and 185 ppm, respectively, verifying aldehyde formation.
Alternatively, furan formation could occur without nucleophiles such as methanol,
 
NH
O
R3
Boc
R1
O
N
O
R3
Boc
R1
OMe
30a
31a-34c
N
O
Boc
R1
R3
AuCl3/MeCN
MeOH, CH2Cl2
R1= H, Me, Ph, and Bn
R3= H, Me, OMe, and Cl
26-29c
H3O+
Path A
Path B CuI
DMF
N
O
Cu
Boc
R1
R3
30b
H2O
M+
Scheme 17.  Proposed pathways of 3-formyl furan formation.
since we observed an unexpected furan formation during our studies on the
Sonogashira coupling reaction. Furans could be generated by an intramolecular
pathway, whereby the lone-pair electrons of N in the enaminone moiety could be
involved in furan formation (Path B, Scheme 17). Adventitious water could also play
a role in these reactions.
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In 2006, Pal and co-workers published the results of Sonogashira coupling
reactions as a continuation of their research on 2-substituted 3-iodo-1H-quinolin-4-
one to synthesize furoquinolines as shown in Scheme 18.54 They observed furan
formation as well as coupling products during the Sonogashira reaction. They claimed
that the N-H of the quinolone ring was responsible for the cyclization after the
coupling step (Eq.1) because they only isolated the coupling product when methyl 3-
iodo-1-methyl-4-oxo-1,4-dihydroquinoline-2-carboxylates with terminal alkynes
were treated under the Sonogashira reaction conditions (Eq. 2). They did not observe
the formation of furoquinoline.
N
H
O
I
C6H5 N
O
R
C6H5
PdCl2(PPh3)2, CuI
R
Et3N, DMF
75-80 °C, 2h, 80%
R= C(OH)Me2
N
O
I
CO2CH3
Pd/C, PPh3, CuI
R1
Et3N, DMF
75-80 °C, 2h, 70%
N
O
CO2CH3
R1
R1= C6H5
Eq. 1
Eq. 2
Scheme 18. Furan formation during the Sonogashira coupling reaction.54
In 2005, furan formation by Cu-mediated cyclization was reported by
Yamamoto and co-workers.55 In their study, Cu-mediated cyclization of 2-(1-
alkynyl)-2-alken-1-ones occurred in the presence of alcohols with a catalytic amount
of Cu salt in DMF at 80 °C. We used 10 % Cu(I) in DMF at room temperature,  in
order to suppress the formation of undesired double addition products. Consequently,
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some of our enaminone substrates underwent Cu-mediated cyclization while others
did not. N-Boc-iodo enaminone 25a, for instance, was converted to two major
products after Sonogashira coupling reactions (Scheme 16 and Table 4), in 2:1 ratio
of 27a to 32a based on 1H NMR.
Therefore, the formations of highly substituted furan analogues were achieved
by two methods. Au(III)-catalyzed cyclization and Cu(I)-mediated cyclization55
during the Sonogashira reaction, both effected furan formation. Moreover, a library of
16 compounds of functionalized furans was constructed via Sonogashira reaction and
Au(III)-catalyzed cyclization in moderate to excellent yield (Table 4). Finally,
construction of the library of functionalized furans from an enaminone scaffold
demonstrated useful opportunities for the synthesis of diversity libraries.
2.4 Conclusion
There are many biologically active compounds containing a furan moiety as a
structural unit. We hypothesized that highly substituted furans can be synthesized
using Au(III)-catalyzed cyclization on enaminone derivatives functionalized with an
arylalkynyl group at C5. A library of functionalized furans was constructed in
moderate to excellent yields.
Enaminones were prepared through three different routes with various starting
materials, such as β-amino acids, piperidones, and pyridone. Using N-Boc-protected
pyridone provided excellent opportunities for the syntheses of various enaminones
toward molecular library construction. Palladium-catalyzed Sonogashira coupling
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reactions of enaminones were successfully carried out under mild conditions. We also
observed furan formation during the coupling reaction of substrates 22 and 25a.
Highly substituted furans were prepared by Au(III) and Cu(I)-catalyzed
cyclization. Further investigations should be carried out to evaluate the role of
nucleophiles for the Au(III)-catalyzed cyclization as well as the elimination process
during the cyclization reaction. It is necessary to investigate the furan formation by
Cu(I)-mediated cyclization in future studies. Finally, the molecular library of
functionalized furans can be utilized for the syntheses of sub-libraries in future
studies.
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Experimental Section
General Method
All starting materials and reagents are commercially available unless otherwise
specified. 1H NMR and 13C NMR were recorded on a Bruker DRX400 MHz (400 and
100 MHz, respectively), or DRX 500 MHz (500 and 125.5 MHz, respectively). All
NMR samples were dissolved in CDCl3 and the spectra were recorded in parts per
million (ppm). All abbreviations are as following: s, singlet; d, doublet; t, triplet; br s,
broad singlet; m, multiplet; dd, a set of doublet. High-resolution mass spectra
(HRMS) were provided by the Bruker BioTOF II mass spectrometer with
electrospray ionization (ESI) method.
(S)-2-Benzyl-5-iodo-2,3-dihydropyridin-4(1H)-one (15).
N
H
O
I
Ph H
(S)-2-Benzyl-2,3-dihydropyridin-4(1H)-one (14 ) (14.0 mg, 0.075 mmol) was
dissolved in dry CH2Cl2 (3 mL) under N2 at room temperature. Then the solution of I2
(29.0 mg, 0.11 mmol) in CH2Cl2 (3 mL) was added and subsequently Et3N (1.0 µL,
0.08 mmol) was added. The resulting mixture was stirred for 30 min. The solution
was diluted with CH2Cl2.   The solvent was removed under reduced pressure. The
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crude mixture was purified by silica gel column chromatography (5% Methanol in
CH2Cl2) to afford 22 mg (94%) of the product as a yellow powder. mp 124-126 °C; Rf
0.71 (5% Methanol in CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 7.5 (d, J = 6.6 Hz,
1H), 7.3-7.1 (m, 5H), 5.1 (br s, 1H), 3.9 (m, 1H), 2.9-2.8 (dd, J = 5.1, 13.7 Hz, 1H),
2.8-2.7 (m, 2H), 2.6-2.5 (dd, J = 3.7, 12.4 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ
185.7, 156.3, 135.4, 128.6, 128.1, 126.3, 97.5, 54.6, 41.3, 40.1; HRMS (TOF MS
ESI) m/z calcd for C12H12INO [M+H]+ 314.0042; found 314.0024.
tert-Butyl 5-Iodo-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (22).
N
O
Boc
I
A mixture (96.8 mg) of tert-butyl 4-oxo-3,4-dihydropyridine-1(2H)-carboxylate and
1-Boc-4-piperidone (56:44 ratio, based on 1H NMR) was dissolved in dry CH2Cl2 (17
mL) under N2 at room temperature. Then the solution of I2 (141 mg, 0.561 mmol) in
CH2Cl2 (11 mL) was added dropwise. Immediately, N,N-4-dimethylaminopyridine
(128.6 mg, 1.020 mmol) was added and the resulting mixture was stirred overnight.
The reaction mixture was diluted with CH2Cl2.  Saturated NH4Cl was added at 0 °C.
Then, the organic layer was extracted with CH2Cl2. The combined organic layers
were washed with brine and dried over Na2SO4, filtered and then concentrated under
reduced pressure. The crude mixture was purified by silica gel column
chromatography (1: 5 EtOAc/ hexanes) to afford 57 mg (53%) of the product as a
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white solid. mp 106-108 °C; Rf 0.46 (1:2 EtOAc/hexanes); 1H NMR (400 MHz,
CDCl3): δ 8.3 (br s, 1H), 4.0 (t, J = 7.2, 7.5 Hz 2H), 2.9 (t, J = 7.4, 7.3 Hz, 2H), 1.5
(s, 9H); 13C NMR (100 MHz, CDCl3): δ 186.4, 149.1, 148.5, 83.4, 74.0, 41.4, 33.5,
27.1; HRMS (TOF MS ESI) m/z calcd for C10H15INO3 [M+H]+ 324.0096; found
324.0078.
tert-Butyl 4-Oxo-3,4-dihydropyridine-1(2H)-carboxylate (24).
N
O
Boc
IBX (28.07g, 100.2 mmol) and 4-methoxypyridine-N-oxide (MPO) (12.59 g, 100.2
mmol) were added and dissolved in DMSO (129.0 mL) under Argon gas at room
temperature and then stirred for 30 min. Then 1-Boc-4-piperidone (15.4 g, 77.1
mmol) was added and CH2Cl2 (64.0 mL) was added. The resulting mixture stirred for
3 days. Reaction mixture was diluted with 5% NaHCO3 and the organic layer was
extracted with ethyl ether. Combined organic layers were filtered through a pad of
celite and washed with saturated NaHCO3, H2O and brine. Then the organic layer was
dried over Na2SO4, filtered and concentrated under reduced pressure. The 1H NMR of
the crude mixture (12.74 g) was shown 53% of desired product and 47 % of starting
materials. Rf 0.52 (1:1 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): 7.8 (br s, 1H),
5.3 (d, J = 8.2 Hz, 1H), 3.9 (t, J = 7.3, 2H), 2.5 (t, J = 7.3, Hz, 2H), 1.5 (s, 9H); 13C
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NMR (100 MHz, CDCl3): δ193.6, 151.3, 144.0, 111.9, 83.5, 41.9, 35.7, 28.1; HRMS
(TOF MS ESI) m/z calcd for C10H15INO3 [M+H]+ 324.0096; found 324.0078.
tert-Butyl 2-Methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (24a).
N
O
Boc
tert-Butyl 4-oxopyridine-1(4H)-carboxylate (10.0 g, 51.2 mmol) was dissolved in
THF (450 mL) under Ar at room temperature. TMSCl (9.50 mL, 76.8 mmol) was
added and the resulting mixture was cooled to -78 °C. The reaction mixture was
stirred for 30 min at -78 °C, and then MeMgBr (3M in Et2O, 39.3 mL, 117.8 mmol)
was added slowly. The reaction mixture was stirred overnight and the reaction
temperature warmed to room temperature while stirring. The reaction mixture was
diluted with EtOAc then quenched with 10% HCl at 0 °C. The resulting mixture was
stirred for 10 min. and then the organic layer was extracted with EtOAc. The
combined organic layers were washed with Brine then dried over Na2SO4, filtered
and concentrated under reduced pressure. The crude mixture was purified by silica
gel column chromatography (1: 1 EtOAc/ hexanes) to afford 8.55 g (79%) of the
product as a yellow solid. Rf 0.62 (1:1 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3):
δ 7.7 (d, J = 7.8 Hz, 1H), 5.3 (d, J = 8.2 Hz, 1H), 4.7 (t, J = 5.8 Hz, 1H), 2.9 (dd, J =
6.8, 16.4 Hz, 1H), 2.3 (t, J = 16.4 Hz, 1H), 1.6 (s, 9H), 1.3 (d, J = 6.7 Hz, 3H) ;13C
NMR (100 MHz, CDCl3): δ 191.1, 150.0, 139.9, 103.7, 81.3, 46.9, 39.9, 26.1, 14.6;
28
HRMS (BioTOF II ESI) m/z calcd for C11H16INO3 [M+Na]+ 234.1101; found
234.1110.
tert-Butyl 4-Oxo-2-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (24b).
N
O
Boc
Ph
tert-Butyl 4-oxopyridine-1(4H)-carboxylate (10.0 g, 51.2 mmol) was dissolved in
THF (400 mL) under Ar at room temperature. TMSCl (10.0 mL, 76.8 mmol) was
added and the resulting mixture was cooled to -78 °C. The reaction mixture was
stirred for 30 min at -78 °C, and then PhMgBr (1.0 M in Et2O, 56.1 mL, 56.3 mmol)
was added slowly. The reaction mixture was stirred overnight and the reaction
temperature warmed to room temperature while stirring. The reaction mixture was
diluted with EtOAc then quenched with 10% HCl at 0 °C. The resulting mixture was
stirred for 10 min. and then the organic layer was extracted with EtOAc. The
combined organic layers were washed with Brine then dried over Na2SO4, filtered
and concentrated under reduced pressure. The crude mixture was purified by silica
gel column chromatography (1: 3 EtOAc/ hexanes) to afford 7.96 g (57 %) of the
product as a white solid. Rf 0.63 (1:1 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3):
δ 8.0 (d, J = 8.3 Hz, 1H), 7.3-7.2 (m, 5H), 5.7 (d, J = 7.2 Hz, 1H), 5.3 (d,  J = 7.7 Hz,
1H), 3.2-3.1 (dd, J = 7.7, 16.5 Hz, 1H), 2.8 (d, J = 16.5 Hz, 1H),1.4 (s, 9H); 13C NMR
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(100 MHz, CDCl3): δ 191.9, 151.2, 143.0, 138.8, 128.6, 127.6, 125.6, 106.8, 83.5,
55.6, 41.6, 28.0.   
tert-Butyl 2-Benzyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (24c).
N
O
Boc
Bn
tert-Butyl 4-oxopyridine-1(4H)-carboxylate (5.00 g, 25.5 mmol) was dissolved in
THF (250 mL) under Ar at room temperature. TMSCl (5.00 mL, 38.3 mmol) was
added and the resulting mixture was cooled to -78 °C. The reaction mixture was
stirred for 30 min at -78 °C, then BnMgCl (2.0 M in Et2O, 29.3 mL, 58.7 mmol) was
added slowly. The reaction mixture was stirred overnight and the reaction
temperature warmed to room temperature while stirring. The reaction mixture was
diluted with EtOAc then quenched with 10% HCl at 0 °C. The resulting mixture was
stirred for 10 min. and then the organic layer was extracted with EtOAc. The
combined organic layers were washed with Brine then dried over Na2SO4, filtered
and concentrated under reduced pressure. The crude mixture was purified by silica
gel column chromatography (1: 3 EtOAc/ hexanes) to afford 5.87g (80%) of the
product as a white solid. Rf 0.53 (1:1 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3):
δ 7.7 (br s, 1H), 7.3-7.1 (m, 5H), 5.3 (br s, 1H), 4.6 (br s, 1H), 2.9 (dd, J = 6.2, 13.2
Hz, 1H), 2.7 (dd, J = 9.0, 13.2 Hz, 1H), 2.6 (dd, J = 1.8, 16.5 Hz, 1H), 2.3 (d, J = 16.5
Hz, 1H), 1.4 (s, 9H); 13C NMR (100 MHz, CDCl3): δ  193.2, 151.0, 142.0, 136.8,
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129.6, 128.7, 126.9, 106.4, 83.4, 54.3, 38.7, 36.2, 27.9; HRMS (BioTOF II ESI) m/z
calcd for C17H21NNaO3 [M+Na]+310.1414; found 310.1403.
 tert-Butyl 5-Iodo-2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (25a).
N
O
Boc
I
tert-Butyl 2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (24a) (911.0 mg,
4.310 mmol) was dissolved in dry CH2Cl2 (70 mL) under N2 at room temperature.
Then N-iodo-succinimide (4.687 g, 20.68 mmol) was added and the resulting mixture
stirred for 3 days. The solution was diluted with CH2Cl2.  The reaction was quenched
with H2O at 0 °C. The organic layer was extracted with CH2Cl2. The combined
organic layers were washed with brine and dried over Na2SO4, filtered and then
concentrated under reduced pressure.  The crude mixture was purified by silica gel
column chromatography (1: 3 EtOAc/ hexanes) to afford 986 mg (68%) of the
product as a yellow solid. mp 133 -134 °C; Rf 0.43 (1:3 EtOAc/hexanes); 1H NMR
(400 MHz, CDCl3): δ 8.2 (s, 1H), 4.7 (m, 1H), 3.0 (dd, J = 6.7, 16.3 Hz, 1H), 2.6 (dd,
J = 1.6, 16.3 Hz, 1H), 1.6 (s, 9H), 1.3 (d, J= 6.7 Hz, 3H); 13C NMR (100 MHz,
CDCl3): δ 188.2, 149.8, 147.3, 84.2, 73.2, 49.3, 40.6, 28.0, 16.8; HRMS (BioTOF II
ESI) m/z calcd for C11H16INO3 [M+Na]+ 360.0067; found 360.0067.
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tert-Butyl 5-Iodo-4-oxo-2-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (25b).
N
O
Boc
I
Ph
tert-Butyl 4-oxo-2-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (24b) (499.0 mg,
1.850 mmol) was dissolved in dry CH2Cl2 (40 mL) under N2 at room temperature.
Then N-iodo-succinimide (1.02 g, 4.52) mmol was added and the resulting mixture
stirred for 3 days. The solution was diluted with CH2Cl2.  The reaction was quenched
with H2O at 0 °C. The organic layer was extracted with CH2Cl2. The combined
organic layers were washed with brine and dried over Na2SO4, filtered and then
concentrated under reduced pressure.  The crude mixture was purified by silica gel
column chromatography (1: 3 EtOAc/ hexanes) to afford 540 mg (73%) of the
product as a yellowish powder. mp 100 -102 °C; Rf 0.42 (1:3 EtOAc/hexanes); 1H
NMR (400 MHz, CDCl3): δ 8.5 (s, 1H), 7.3-7.1 (m, 5H), 5.7 (d, J = 7.0 Hz, 1H), 3.2
(dd, J = 7.4, 16.4 Hz, 1H), 3.0 (dd, J = 1.7, 16.4 Hz, 1H), 1.4 (s, 9H); 13C NMR (100
MHz, CDCl3): δ  185.6, 149.8, 147.9, 137.9, 128.6, 127.8, 125.2, 84.1, 74.2, 55.7,
40.4, 27.6; HRMS (BioTOF II ESI) m/z calcd for C16H18INO3 [M+Na]+ 422.0224;
found 422.0233.
tert-Butyl 2-Benzyl-5-iodo-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (25c).
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N
O
Boc
I
Bn
tert-Butyl 2-benzyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (24c) (495.0 mg,
1.750 mmol) was dissolved in dry CH2Cl2 (40 mL) under N2 at room temperature.
Then N-iodo-succinimide (0.956 g, 4.20 mmol) was added and the resulting mixture
stirred overnight. The solution was diluted with CH2Cl2.  The reaction was quenched
with H2O at 0 °C. The organic layer was extracted with CH2Cl2. The combined
organic layers were washed with brine and dried over Na2SO4, filtered and then
concentrated under reduced pressure.  The crude mixture was purified by silica gel
column chromatography (1: 3 EtOAc/ hexanes) to afford 598 mg (83%) of the
product as a yellowish powder. mp 134 °C; Rf 0.47 (1:3 EtOAc/hexanes); 1H NMR
(400 MHz, CDCl3): δ 8.3 (br s, 1H), 7.3-7.1 (m, 5H), 4.7 (br s, 1H), 3.0 (dd, J = 6.2,
13.2 Hz, 1H), 2.8 (dd, J = 9.0, 13.2 Hz, 1H), 2.7 (dd, J = 1.8, 16.5 Hz, 1H), 1.5 (s,
9H); 13C NMR (100 MHz, CDCl3): δ 186.8, 149.8, 147.4, 136.2, 129.5, 128.7, 127.0,
84.3, 74.0, 54.7, 37.6, 36.4, 28.0; HRMS (BioTOF II ESI) m/z calcd for C17H20INO3
[M+Na]+ 436.038; found 436.0384.
tert-Butyl 4-Oxo-5-(4-tolylethynyl)-3,4-dihydropyridine-1(2H)-carboxylate (26a).
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tert-Butyl 5-iodo-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (22) (72.0 mg, 0.223
mmol), PdCl2(PPh3)2 (8.6 mg, 0.012 mmol) and CuI (21.5 mg, 0.113 mmol) were
dissolved in dry DMF (2.2 mL) under N2 at room temperature. The reaction mixture
was stirred for 5 min and 1-ethynyl-4-methylbenzene (5.0 µL, 0.34 mmol) was added
and then, Et3N (25.0 µL, 1.78 mmol) was added slowly. The reaction mixture was
stirred overnight. The solution was diluted with EtOAc and quenched with saturated
NH4Cl at 0 °C. The organic layer was extracted with EtOAc. The combined organic
layers were washed with water, brine and then, dried over anhydrous Na2SO4. The
solvent was removed under reduced pressure. The crude mixture was purified by
silica gel column chromatography (1: 5 EtOAc/ hexanes) to afford 60 mg (86%) of
the product as a yellow powder. mp 140 -142 °C; Rf 0.22 (1:3 EtOAc/hexanes); 1H
NMR (400 MHz, CDCl3): δ 8.2 (br s, 1H), 7.4 (d, J= 8.1 Hz, 2H), 7.2 (d, J = 7.9 Hz,
2H), 4.0 (t, J = 7.4 Hz, 2H), 2.7 (t, J = 7.4 Hz, 2H), 2.4 (s, 3H), 1.6 (s, 9H); 13C NMR
(100 MHz, CDCl3): δ  190.4, 150.5, 147.1, 138.2, 131.5, 128.7, 120.1, 103.3, 91.3,
84.4, 81.7, 42.3, 35.6, 28.0, 21.5.
tert-Butyl 5-((4-Methoxyphenyl)ethynyl)-4-oxo-3,4-dihydropyridine-1(2H)-
carboxylate (26b).
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tert-Butyl 5-iodo-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (22) (99.6 mg, 0.309
mmol), PdCl2(PPh3)2 (10.4 mg, 0.015 mmol) and CuI (28.2 mg, 0.155 mmol) were
dissolved in dry DMF (3.1 mL) under N2 at room temperature. The reaction mixture
was stirred for 5 min and 1-ethynyl-4-methoxybenzene (6.0 µL, 0.46 mmol) was
added and then, Et3N (34.0 µL, 2.47 mmol) was added slowly. The reaction mixture
was stirred overnight. The solution was diluted with EtOAc and quenched with
saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc. The combined
organic layers were washed with water, brine and then dried over anhydrous Na2SO4.
The solvent was removed under reduced pressure. The crude mixture was purified by
silica gel column chromatography (1: 3 EtOAc/ hexanes) to afford 65 mg (64%) of
the product as a yellow oil.; R f 0.19 (1:3 EtOAc/hexanes); 1H NMR (400 MHz,
CDCl3): δ 8.1 (br s, 1H), 7.4 (d, J = 8.1 Hz, 2H), 6.7 (d, J = 7.9 Hz, 2H), 4.0 (t, J =
7.4 Hz, 2H), 3.8 (s, 3H), 2.6 (t, J = 7.4 Hz, 2H), 1.5 (s, 9H); 13C NMR (100 MHz,
CDCl3): δ 188.9, 158.0, 145.3, 131.6, 124.0, 112.7, 112.3, 101.9, 89.5, 82.7, 79.5,
53.8, 40.7, 34.1, 26.8; HRMS (BioTOF II ESI) m/z calcd for C19H21NNaO4 [M+Na]+
350.1363; found 350.1381.
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ter t -Butyl  2-Methyl-4-oxo-5-(phenylethynyl)-3,4-dihydropyridine-1(2H)-
carboxylate (27).
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tert-Butyl 5-iodo-2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (25a)
(995.0 mg, 2.951 mmol), PdCl2(PPh3)2  (136.0 mg, 0.1938 mmol) and CuI (294.0 mg,
1.544 mmol) were dissolved in dry DMF (25 mL) under N2 at room temperature. The
reaction mixture was stirred for 5 min and 1-ethynylbenzene (50.0 µL, 4.43 mmol)
was added and then Et3N (3.30 mL, 23.8 mmol) was added slowly. The reaction
mixture was stirred overnight. The solution was diluted with EtOAc and quenched
with saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc. The
combined organic layers were washed with water, brine and then, dried over
anhydrous Na2SO4. The solvent was removed under reduced pressure. The crude
mixture was purified by silica gel column chromatography (1: 6 EtOAc/ hexanes) to
afford 747 mg (92%) of the product as a yellow powder. mp 92- 93 °C; Rf 0.21 (1:6
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 8.0 (s, 1H), 7.4 -7.2 (m, 5H), 4.0
(m, 1H), 2.8 (dd, J = 6.6, 16.0 Hz, 1H), 2.3 (dd, J = 1.4, 16.3 Hz, 1H), 1.5 (s, 9H), 1.2
(d, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 189.9, 154.0, 145.2, 131.2,
128.0, 127.0, 123.3, 102.1, 91.0, 84.2, 83.8, 49.2, 41.7, 27.8, 16.9; HRMS (BioTOF II
ESI) m/z calcd for C19H21NO3 [M+Na]+ 334.1414; found 334.1423.
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t er t -Butyl  2-Methyl-4-oxo-5-(p-tolylethynyl)-3,4-dihydropyridine-1(2H)-
carboxylate (27a).
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tert-Butyl 5-iodo-2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (25a)
(996.0 mg, 2.951 mmol), PdCl2(PPh3)2 (142.0 mg, 0.1938 mmol) and CuI (291.0 mg,
1.544 mmol) were dissolved in dry DMF (20 mL) under N2 at room temperature. The
reaction mixture was stirred for 5 min and 1-ethynyl-4-methylbenzene (0.60 mL, 4.4
mmol) was added and then Et3N (3.30 mL, 23.8 mmol) was added slowly. The
reaction mixture was stirred overnight. The solution was diluted with EtOAc and
quenched with saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc.
The combined organic layers were washed with water, brine and then, dried over
anhydrous Na2SO4. The solvent was removed under reduced pressure. The crude
mixture was purified by silica gel column chromatography (1: 6 EtOAc/ hexanes) to
afford 489 mg (51%) of the product as a yellow powder. mp 104-106 °C; Rf 0.21 (1:6
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 8.0 (br s, 1H), 7.3 (d, J = 8.1 Hz,
2H), 7.0 (d, J = 7.9 Hz, 2H), 4.6 (s, 1H), 2.8 (dd, J = 6.7, 16.4 Hz, 1H), 2.4 (dd, J =
1.6, 16.4 Hz, 1H), 2.3 (s, 3H), 1.5 (s, 9H), 1.2 (d, J = 5.2 Hz, 3H); 13C NMR (100
MHz, CDCl3): δ 190.1, 150.2, 145.1, 138.1, 129.2, 123.5, 120.1, 105.7, 94.7, 84.2,
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81.8, 46.0, 41.7, 28.3, 21.2, 16.6; HRMS (BioTOF II ESI) m/z  calcd for
C20H23NNaO3 [M+Na]+ 348.157; found 348.1581.
tert-Butyl 5-((4-Methoxyphenyl)ethynyl)-2-methyl-4-oxo-3,4-dihydropyridine-
1(2H)-carboxylate (27b).
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tert-Butyl 5-iodo-2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (25a)
(998.0 mg, 2.951 mmol), PdCl2(PPh3)2 (145.0 mg, 0.1938 mmol) and CuI (291.0 mg,
1.544 mmol) were dissolved in dry DMF (20 mL) under N2 at room temperature. The
reaction mixture was stirred for 5 min and 1-ethynyl-4-methoxybenzene (0.60 mL,
4.4 mmol) was added and then Et3N (3.30 mL, 23.8 mmol) was added slowly. The
reaction mixture was stirred overnight. The solution was diluted with EtOAc and
quenched with saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc.
The combined organic layers were washed with water, brine and then, dried over
anhydrous Na2SO4. The solvent was removed under reduced pressure. The crude
mixture was purified by silica gel column chromatography (1: 6 EtOAc/ hexanes) to
afford 516 mg (51%) of the product as a yellow powder. mp 104-106 °C; Rf 0.2 (1:6
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 8.0 (br s, 1H), 7.4 (d, J = 9.4 Hz,
2H) 6.8 (d, J = 9.4 Hz, 2H) 4.7 (br t, J = 6.6 Hz 1H), 3.7 (s, 3H), 2.9-2.8 (dd, J = 6.7,
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16.4 Hz, 1H), 2.4 (dd, J = 1.6, 16.3 Hz, 1H), 1.5 (s, 9H), 1.2 (d, J = 6.7 Hz, 3H); 13C
NMR (100 MHz, CDCl3): δ 190.1, 159.4, 150.1, 144.8, 133.0, 115.3, 113.8, 102.6,
90.9, 84.1, 81.1, 55.1, 49.3, 41.6, 28.5, 16.8; HRMS (BioTOF II ESI) m/z calcd for
C20H23NNaO4 [M+Na]+ 364.1519; found 364.1503.
tert-Butyl 5-((4-Chlorophenyl)ethynyl)-2-methyl-4-oxo-3,4-dihydropyridine-
1(2H)-carboxylate (27c).
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tert-Butyl 5-iodo-2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (25a)
(302.0 mg, 0.8957 mmol), PdCl2(PPh3)2 (43.0 mg, 0.0613 mmol) and CuI (88.0 mg,
0.462 mmol) were dissolved in dry DMF (9 mL) under N2 at room temperature. The
reaction mixture was stirred for 5 min and 4-chloro-1-ethynylbenzene (186.0 mg,
1.350 mmol) was added and then Et3N (0.99 mL, 7.2 mmol) was added slowly. The
reaction mixture was stirred for 3 h. The solution was diluted with EtOAc and
quenched with saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc.
The combined organic layers were washed with water, brine and then, dried over
anhydrous Na2SO4. The solvent was removed under reduced pressure. The crude
mixture was purified by silica gel column chromatography (1: 6 EtOAc/ hexanes) to
afford 201 mg (64%) of the product as a yellow powder. 1H NMR (400 MHz,
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CDCl3): δ 8.0 (s, 1H), 7.4 (d, J = 8.5 Hz, 2H), 7.2 (d, J = 8.5 Hz, 2H), 4.6 (m, 1H),
2.8 (dd, J = 6.7, 16.5 Hz, 1H), 2.4 (dd, J = 1.5, 16.4 Hz, 1H), 1.5 (s, 9H), 1.2 (d, J =
5.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 190.2, 150.1, 145.7, 134.1, 132.8,
128.7, 121.9, 101.9, 90.1, 84.5, 83.6, 49.3, 33.8, 28.1, 14.3; HRMS (BioTOF II ESI)
m/z calcd for C19H20NaClO3 [M+Na]+ 368.1024; found 368.1011.
ter t-Butyl  4-Oxo-2-Phenyl-5-(phenylethynyl)-3,4-dihydropyridine-1(2H)-
carboxylate (28).
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tert-Butyl 2-phenyl-5-iodo-4-oxo-3,4-dihydropyridin-1(2H)-carboxylate (25b) (302.0
mg, 0.7569 mmol), PdCl2(PPh3)2 (28.0 mg, 0.0399 mmol) and CuI (72.0 mg, 0.378
mmol) were dissolved in dry DMF (9 mL) under N2 at room temperature. The
reaction mixture was stirred for 5 min and 1-ethynylbenzene (12.0 µL, 1.10 mmol)
was added and then Et3N (84.0 µL, 5.84 mmol) was added slowly. The reaction
mixture stirred overnight. The solution was diluted with EtOAc and quenched with
saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc. The combined
organic layers were washed with water, brine and then, dried over anhydrous Na2SO4.
The solvent was removed under reduced pressure. The crude mixture was purified by
silica gel column chromatography (1: 3 EtOAc/ hexanes) to afford 226 mg (81%) of
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the product as a yellow powder. mp 116 °C; Rf 0.37 (1:3 EtOAc/hexanes); 1H NMR
(400 MHz, CDCl3): δ 8.3 (s, 1H), 7.4-7.1 (m, 10H), 5.6 (d, J = 7.0 Hz, 1H), 3.1 (dd, J
= 7.6,16.5 Hz, 1H), 2.8 (dd, J = 1.7, 16.5 Hz, 1H), 1.4 (s, 9H); 13C NMR (100 MHz,
CDCl3): δ 189.1, 150.6, 146.2, 138.3, 131.6, 129.0, 128.8, 128.2, 128.1, 125.7, 123.8,
103.4, 91.4, 84.6, 82.5, 56.0, 41.8, 27.9; HRMS (BioTOF II ESI) m/z calcd for
C24H23NO3 [M+Na]+ 396.157; found 396.1551.
ter t -Butyl  4-Oxo-2-phenyl-5-(p-tolylethynyl)-3,4-dihydropyridine-1(2H)-
carboxylate (28a).
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tert-Butyl 2-phenyl-5-iodo-4-oxo-3,4-dihydropyridin-1(2H)-carboxylate (25b) (302.0
mg, 0.7565 mmol), PdCl2(PPh3)2 (29.0 mg, 0.0413 mmol) and CuI (75.0 mg, 0.394
mmol) were dissolved in dry DMF (9 mL) under N2 at room temperature. The
reaction mixture was stirred for 5 min and 1-ethynyl-4-methylbenzene (14.4 µL, 1.13
mmol) was added and then Et3N (84.0 µL, 5.84 mmol) was added slowly. The
reaction mixture stirred overnight. The solution was diluted with EtOAc and
quenched with saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc.
The combined organic layers were washed with water, brine and then, dried over
anhydrous Na2SO4. The solvent was removed under reduced pressure. The crude
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mixture was purified by silica gel column chromatography (1: 6 EtOAc/ hexanes) to
afford 283 mg (98%) of 22a as a yellow powder. mp 134-136 °C; R f 0.23 (1:6
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 8.3 (s, 1H), 7.3-7.0 (m, 9H), 5.6 (d,
J = 7.0 Hz 1H), 3.1 (dd, J = 7.5, 16.5 Hz, 1H), 2.8 (dd, J = 1.5, 16.5 Hz, 1H), 2.2 (s,
3H), 1.4 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 189.1, 150.6, 146.0, 138.3, 138.2,
131.5, 129.0, 128.8, 128.1, 125.7, 120.1, 103.6, 91.5, 84.5, 81.7, 55.9, 41.8, 27.9,
21.5; HRMS (BioTOF II ESI) m/z calcd for C25H25NO3 [M+Na]+ 410.1727; found
410.1740.
tert-Butyl 5-((4-Methoxyphenyl)ethynyl)-4-oxo-2-phenyl-3,4-dihydropyridine-
1(2H)-carboxylate (28b).
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tert-Butyl 2-phenyl-5-iodo-4-oxo-3,4-dihydropyridin-1(2H)-carboxylate (25b) (308.0
mg, 0.7715 mmol), PdCl2(PPh3)2 (28.0 mg, 0.0399 mmol) and CuI (74.0 mg, 0.389
mmol) were dissolved in dry DMF (9 mL) under N2 at room temperature. The
reaction mixture was stirred for 5 min and 1-ethynyl-4-methoxybenzene (15.0 µL,
1.13 mmol) was added and then Et3N (84.0 µL, 5.84 mmol) was added slowly. The
reaction mixture stirred overnight. The solution was diluted with EtOAc and
quenched with saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc.
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The combined organic layers were washed with water, brine and then dried over
anhydrous Na2SO4. The solvent was removed under reduced pressure. The crude
mixture was purified by silica gel column chromatography (1: 3 EtOAc/ hexanes) to
afford 267 mg (86%) of 22b as a yellow powder. mp 138-140 °C; R f 0.30 (1:3
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 8.2 (br s, 1H), 7.4-6.7 (m, 9H), 5.6
(d, J = 7.0 Hz, 1H), 3.1 (dd, J = 7.5, 16.4 Hz, 1H), 2.9 (d, J = 1.7 Hz, 1H), 1.4 (s, 9H);
13C NMR (100 MHz, CDCl3): δ 189.2, 159.5, 150.6, 145.8, 138.2, 133.1, 128.8,
128.1, 126.2, 125.2, 114.1, 103.7, 91.3, 84.5, 80.9, 55.9, 55.2, 41.8, 27.8; HRMS
(BioTOF II ESI) m/z calcd for C25H25NO3 [M+Na]+ 426.1676; found 426.1667.
(±)tert-Butyl 5-((4-Chlorophenyl)ethynyl)-4-oxo-2-phenyl-3,4-dihydropyridine-
1(2H)-carboxylate (28c).
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tert-Butyl 2-phenyl-5-iodo-4-oxo-3,4-dihydropyridin-1(2H)-carboxylate (25b) (308.0
mg, 0.7715 mmol), PdCl2(PPh3)2 (28.0 mg, 0.0399 mmol) and CuI (72.0 mg, 0.388
mmol) were dissolved in dry DMF (9 mL) under N2 at room temperature. The
reaction mixture was stirred for 5 min and 1-chloro-4-ethynylbenzene (160.0 mg,
1.171 mmol) was added and then Et3N (84.0 µL, 5.84 mmol) was added slowly. The
reaction mixture stirred overnight. The solution was diluted with EtOAc and
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quenched with saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc.
The combined organic layers were washed with water, brine and then dried over
anhydrous Na2SO4. The solvent was removed under reduced pressure. The crude
mixture was purified by silica gel column chromatography (1: 4 EtOAc/ hexanes) to
afford 269 mg (86%) of the product as a yellow powder. mp 132-134 °C; Rf 0.43 (1:3
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 8.3 (s, 1H), 7.3-7.1 (m, 9H), 5.6 (d,
J = 7.1 Hz 1H), 3.1 (dd, J = 7.5, 16.5 Hz, 1H), 1.4 (s, 9H); 13C NMR (100 MHz,
CDCl3): δ 189.0, 150.1, 146.4, 138.1, 134.0, 132.4, 128.8, 128.3, 127.8, 125.3, 121.7,
103.1, 90.3, 84.5, 83.5, 56.7, 41.8, 27.9; HRMS (BioTOF II ESI) m/z calcd for
C24H22ClNO3 [M+Na]+ 430.118; found 430.1186.
tert-Butyl 2-Benzyl-4-oxo-5-(phenylethynyl)-3,4-dihydropyridine-1(2H)-
carboxylate (29).
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tert-Butyl 2-benzyl-5-iodo-4-oxo-3,4-dihydropyridin-1(2H)-carboxylate (25c) (305.1
mg, 0.7383 mmol), PdCl2(PPh3)2 (28.0 mg, 0.0399 mmol) and CuI (80.0 mg, 0.420
mmol) were dissolved in dry DMF (9 mL) under N2 at room temperature. The
reaction mixture was stirred for 5 min and 1-ethynylbenzene (12.0 µL, 1.10 mmol)
was added and then Et3N (81.0 µL, 5.84 mmol) was added slowly. The reaction
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mixture stirred for 3 h. The solution was diluted with EtOAc and quenched with
saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc. The combined
organic layers were washed with water, brine and then dried over anhydrous Na2SO4.
The solvent was removed under reduced pressure. The crude mixture was purified by
silica gel column chromatography (1: 6 EtOAc/ hexanes) to afford 263 mg (92%) of
the product as a yellowish powder. mp 140 -142 °C; Rf 0.54 (1:3 EtOAc/hexanes); 1H
NMR (400 MHz, CDCl3): δ 8.1 (br s, 1H), 7.4-7.0 (m, 10H), 4.6 (br s, 1H), 2.9 (dd, J
= 6.3, 13.2 Hz, 1H), 2.7 (dd, J = 9.1, 13.2 Hz, 1H), 2.6 (dd, J = 6.4, 16.6 Hz, 1H), 2.4
(dd, J = 1.6, 16.6 Hz, 1H), 1.4 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 190.0, 150.1,
145.4, 136.4, 131.2, 129.6, 128.7, 128.2, 128.1, 127.0, 123.3, 102.6, 91.4, 84.3, 82.4,
54.7, 38.7, 36.5, 27.9; HRMS (BioTOF II ESI) m/z calcd for C25H25NO3 [M+Na]+
410.1727; found 410.1737.
tert-Butyl 2-Benzyl-5-(4-toluylethynyl)-3,4-dihydropyridin-1(2H)-carboxylate
(29a).
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tert-Butyl 2-benzyl-5-iodo-4-oxo-3,4-dihydropyridin-1(2H)-carboxylate (25c) (299.6
mg, 0.7260 mmol), PdCl2(PPh3)2 (29.0 mg, 0.0413 mmol) and CuI (86.0 mg, 0.452
mmol) were dissolved in dry DMF (9 mL) under N2 at room temperature. The
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reaction mixture was stirred for 5 min and 1-ethynyl-4-methylbenzene (15.0 µL, 1.08
mmol) was added and then Et3N (81.0 µL, 5.84 mmol) was added slowly. The
reaction mixture  stirred for 3 h. The solution was diluted with EtOAc and quenched
with saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc. The
combined organic layers were washed with water, brine and then dried over
anhydrous Na2SO4. The solvent was removed under reduced pressure. The crude
mixture was purified by silica gel column chromatography (1: 6 EtOAc/ hexanes) to
afford 286 mg (98%) of the product as a yellowish powder. mp 152 -154 °C; Rf 0.30
(1:6 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 8.2 (br s, 1H), 7.4-7.1 (m, 9H),
4.8 (br s, 1H), 3.0 (dd, J = 6.2, 13.2 Hz, 1H), 2.8 (dd, J = 9.3, 13.3 Hz, 1H), 2.7 (dd, J
= 6.4, 16.6 Hz, 1H), 2.5 (dd, J = 1.6, 16.5 Hz, 1H), 2.4 (s, 3H), 1.5 (s, 9H); 13C NMR
(100 MHz, CDCl3): δ 190.1, 150.3, 145.1, 138.1, 136.4, 131.5, 129.6, 128.9, 128.7,
127.0, 120.2, 103.0, 91.5, 84.2, 81.7, 54.6, 38.7, 36.5, 27.9, 21.5; HRMS (BioTOF II
ESI) m/z calcd for C26H27NO3 [M+Na]+ 424.1883; found 424.1883.
tert-Butyl 2-Benzyl-5-((4-methoxyphenyl)ethynyl)-4-oxo-3,4-dihydropyridine-
1(2H)-carboxylate (29b).
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tert-Butyl 2-benzyl-5-iodo-4-oxo-3,4-dihydropyridin-1(2H)-carboxylate (25c) (295.8
mg, 0.7158 mmol), PdCl2(PPh3)2 (29.0 mg, 0.0413 mmol) and CuI (69.0 mg, 0.362
mmol) were dissolved in dry DMF (9 mL) under N2 at room temperature. The
reaction mixture was stirred for 5 min and 1-ethynyl-4-methoxybenzene (15.0 µL,
1.08 mmol) was added and then Et3N (81.0 µL, 5.84 mmol) was added slowly. The
reaction mixture stirred overnight. The solution was diluted with EtOAc and
quenched with saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc.
The combined organic layers were washed with water, brine and then dried over
anhydrous Na2SO4. The solvent was removed under reduced pressure. The crude
mixture was purified by silica gel column chromatography (1: 3 EtOAc/ hexanes) to
afford 280 mg (94%) of the product as a yellow powder. mp 158 -160 °C; Rf 0.44 (1:3
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 8.1 (br s, 1H), 7.4-6.7 (m, 9H), 4.6
(br s, 1H), 3.7 (s, 3H), 2.9 (dd, J = 6.2, 13.1 Hz, 1H), 2.7 (dd, J = 9.2, 13.2 Hz, 1H),
2.6 (dd, J = 6.4, 16.6 Hz, 1H), 2.4 (dd, J = 1.6, 16.6 Hz, 1H), 1.4 (s, 9H); 13C NMR
(100 MHz, CDCl3): δ 190.1, 159.5, 150.2, 144.9, 136.4, 133.0, 129.6, 128.7, 127.0,
115.4, 113.9, 103.2, 91.3, 84.2, 81.0, 55.3, 54.7, 38.7, 36.5, 27.9; HRMS (BioTOF II
ESI) m/z calcd for C26H27NNaO4 [M+Na]+ 440.1832; found 440.1836.
tert-Butyl 2-Benzyl-5-((4-chlorophenyl)ethynyl)-4-oxo-3,4-dihydropyridine-
1(2H)-carboxylate (29c).
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tert-Butyl 2-benzyl-5-iodo-4-oxo-3,4-dihydropyridin-1(2H)-carboxylate (25c) (315.0
mg, 0.7623 mmol), PdCl2(PPh3)2 (29.0 mg, 0.0413 mmol) and CuI (81.0 mg, 0.425
mmol) were dissolved in dry DMF (9 mL) under N2 at room temperature. The
reaction mixture was stirred for 5 min and 1-chloro-4-ethynylbenzene (151 mg, 1.11
mmol) was added and then Et3N (81.0 µL, 5.84 mmol) was added slowly. The
reaction mixture stirred for 2 h. The solution was diluted with EtOAc and quenched
with saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc. The
combined organic layers were washed with water, brine and then dried over
anhydrous Na2SO4. The solvent was removed under reduced pressure. The crude
mixture was purified by silica gel column chromatography (1: 6 EtOAc/ hexanes) to
afford 289 mg (90%) of the product as a brown powder. mp 146 -148 °C; Rf 0.60 (1:3
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 8.1 (br s, 1H), 7.4-7.1 (m, 9H), 4.6
(br s, 1H), 2.9 (dd, J = 6.2, 13.1 Hz, 1H), 2.7 (dd, J = 9.3, 13.1 Hz, 1H), 2.6 (dd, J =
6.0, 16.6 Hz, 1H), 2.4 (d, J = 16.6 Hz, 1H), 1.4 (s, 9H); 13C NMR (100 MHz, CDCl3):
δ 189.9, 150.1, 145.4, 136.3, 133.7, 132.7, 129.0, 128.7, 128.6, 127.0, 121.8, 102.5,
90.3, 84.4, 83.6, 54.7, 38.7, 36.5, 28.2; HRMS (BioTOF II ESI) m/z calcd for
C25H24ClNNaO3 [M+Na]+ 444.1337; found 444.1331.
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tert-Butyl 4-Methoxy-2-p-tolyl-6,7-dihydrofuro[3,2-c]pyridine-5(4H)-carboxylate
(31).
N
O
OMe
Boc
 tert-Butyl 4-oxo-5-(4-tolylethynyl)-3,4-dihydropyridine-1(2H)-carboxylate (26a)
(51.0 mg, 0.164 mmol) was dissolved in dry CH2Cl2 under N2 at room temperature
and stirred for 10 min. Then AuCl3 (1.0 mL, 1.6 mM in CH3CN) solution was added
in one portion and MeOH (0.20 mL, 4.9 mmol) was added. The resulting reaction
mixture was stirred for 5 h. The solvent was removed under reduced pressure. The
crude mixture was purified by preparatory thin layer chromatography (1: 4 EtOAc/
hexanes) to afford 27 mg (63%) of the product as colorless oil. In addition, 12 mg of
starting material was recovered. Rf = 0.76 (product 31, 1/1 EtOAc/ Hexanes); 1H
NMR (400 MHz, CDCl3): δ 7.5 (d, J = 7.0 Hz, 2H), 7.1 (d, J = 7.0 Hz, 2H), 6.6 (s,
1H), 3.5 (s, 3H), 2.9 (m, 2H), 2.6 (m, 2H), 2.4 (s, 3H), 1.5 (s, 9H); 13C NMR (100
MHz, CDCl3): δ 167.7, 154.3, 150.8, 137.1, 129.5, 128.1, 123.6, 118.9, 103.0, 81.0,
80.2, 79.5, 55.6, 36.6, 28.4, 23.6, 21.3; HRMS (BioTOF II ESI) m/z calcd for
C20H27NO4 [M+H]+ 344.1862; found 344.1864.
tert-Butyl 2-(3-Formyl-5-phenylfuran-2-yl)ethylcarbamate (31a).
NH
O
O
Boc
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tert-Butyl 5-iodo-4-oxo-3,4-dihydropyridine-1(2H )-carboxylate (22) (104.0 mg,
0.3219 mmol), PdCl2(PPh3)2 (15.0 mg, 0.0214 mmol) and CuI (30.0 mg, 0.160 mmol)
were dissolved in dry DMF (3.0 mL) under N2 at room temperature. The reaction
mixture was stirred for 5 min and 1-ethynylbenzene (5.0 µL, 0.48 mmol) was added
and then, Et3N (36.0 µL, 2.56 mmol) was added slowly. The reaction mixture stirred
overnight. The solution was diluted with EtOAc and quenched with saturated NH4Cl
at 0 °C. The organic layer was extracted with EtOAc. The combined organic layers
were washed with water, brine and then, dried over anhydrous Na2SO4. The solvent
was removed under reduced pressure. The crude mixture was purified by silica gel
column chromatography (1: 6 EtOAc/ hexanes) to afford 64 mg (67%) of the product
as brown oil. Rf 0.67 (1:3 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 9.9 (s,
1H), 7.6-7.2 (m, 5H), 6.9 (s, 1H), 4.7 (br s, 1H), 3.5 (t, J = 6.3 Hz, 2H), 3.2 (t, J = 6.3
Hz, 2H), 1.4 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 184.8, 161.9, 155.8, 154.1,
129.0, 128.7, 128.4, 124.0, 123.5, 102.5, 79.7, 39.2, 28.4, 27.9; HRMS (BioTOF II
ESI) m/z calcd for C18H21NNaO4 [M+Na]+ 338.1363; found 338.1348.
tert-Butyl 2-(3-Formyl-5-(4-methoxyphenyl)furan-2-yl)ethylcarbamate (31c).
NH
O
O
Boc
OMe
tert-Butyl 5-iodo-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (22) (98.0 mg, 0.303
mmol), PdCl2(PPh3)2 (15.0 mg, 0.0214 mmol) and CuI (30.0 mg, 0.160 mmol) were
dissolved in dry DMF (3.0 mL) under N2 at room temperature. The reaction mixture
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was stirred for 5 min and 1-ethynylbenzene (6.0 µL, 0.45 mmol) was added and then,
Et3N (33.0 µL, 2.40 mmol) was added slowly. The reaction mixture stirred overnight.
The solution was diluted with EtOAc and quenched with saturated NH4Cl at 0 °C.
The organic layer was extracted with EtOAc. The combined organic layers were
washed with water, brine and then, dried over anhydrous Na2SO4. The solvent was
removed under reduced pressure. The crude mixture was purified by silica gel column
chromatography (1: 6 EtOAc/ hexanes) to afford 62 mg (60%) of the product as
yellow oil. Rf 0.51 (1:3 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 9.8 (s, 1H),
7.5 (d, J = 8.5 Hz, 2H), 6.8 (d, J = 8.5 Hz, 2H) 6.7 (s, 1H), 4.7 (br s, 1H), 3.4 (t, J =
6.2 Hz, 2H), 3.1 (t, J = 6.2 Hz, 2H), 1.3 (s, 9H); 13C NMR (100 MHz, CDCl3): δ
184.8, 161.5, 159.7, 155.8, 154.2, 125.7, 125.1, 122.4, 114.1, 100.7, 79.7, 55.3, 39.3,
28.3, 27.6; HRMS (BioTOF II ESI) m/z calcd for C19H23NNaO5 [M+Na]+ 368.1474;
found 368.1468.
tert-Butyl 2-(5-(4-Chlorophenyl)-3-formylfuran-2-yl)ethylcarbamate (31d).
NH
O
O
Boc
Cl
tert-Butyl 5-iodo-4-oxo-3,4-dihydropyridine-1(2H )-carboxylate (22) (503.0 mg,
1.550 mmol), PdCl2(PPh3)2 (58.0 mg, 0.080 mmol) and CuI (148.0 mg, 0.777 mmol)
were dissolved in dry DMF (15.0 mL) under N2 at room temperature. The reaction
mixture was stirred for 5 min and 4-chloro-1-ethynylbenzene (322.0 mg, 2.358 mmol)
was added and then Et3N (1.73 µL, 12.4 mmol) was added slowly. The reaction
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mixture stirred overnight. The solution was diluted with EtOAc and quenched with
saturated NH4Cl at 0 °C. The organic layer was extracted with EtOAc. The combined
organic layers were washed with water, brine and then, dried over anhydrous Na2SO4.
The solvent was removed under reduced pressure. The crude mixture was purified by
CombiFlash chromatography (1: 1 EtOAc/ hexanes) to afford 292 mg (57%) of the
product as a brown powder. mp 98 -100 °C; 1H NMR (400 MHz, CDCl3): δ 9.8 (s,
1H), 7.5 (d, J= 8.5 Hz, 2H), 7.3 (d, J= 8.5 Hz, 2H), 6.8 (s, 1H), 4.7 (br s, 1H), 3.5 (t, J
= 5.8 Hz, 2H), 3.2 (t, J = 6.1 Hz, 2H), 1.4 (s, 9H); 13C NMR (100 MHz, CDCl3): δ
184.7, 162.1, 155.8, 153.0, 134.1, 133.7, 128.9, 127.9, 125.3, 103.0, 79.8, 39.2, 29.7,
27.9; HRMS (BioTOF II ESI) m/z calcd for C18H20ClNNaO4 [M+Na]+ 372.0973;
found 372.0960.
Synthetic procedures of compounds 32-32c: See the procedures of the corresponding
Sonogashira coupling reactions for compounds 27-27c.
 tert-Butyl 1-(3-Formyl-5-phenylfuran-2-yl)propan-2-ylcarbamate (32).
NH
O
O
Boc
15% of 32 were observed by 1H NMR. 1H NMR (400 MHz, CDCl3): δ 9.8 (s, 1H),
7.6 (d, J = 8.4 Hz, 2H), 7.3 (d, J = 7.8 Hz, 2H), 6.8 (s, 1H), 4.6 (br s, 1H), 4.5 (t, J =
6.4 Hz, 1H), 4.0 (m, 2H), 1.3 (s, 9H), 1.2 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz,
CDCl3): δ 185.0, 161.5, 155.0, 150.1, 141.8, 129.5, 127.5, 126.2, 124.0, 102.4, 79.4,
52
46.0, 41.8, 28.3, 16.7; HRMS (BioTOF II ESI) m/z calcd for C19H23NNaO4 [M+Na]+
352.1525; found 352.1546.
tert-Butyl 1-(3-Formyl-5-p-tolylfuran-2-yl)propan-2-ylcarbamate  (32a).
NH
O
O
Boc
Rf 0.42 (1:3 EtOAc/hexanes); 140 mg (14 %), a yellow powder, mp 132-134 °C; 1H
NMR (400 MHz, CDCl3): δ 9.8 (s, 1H), 7.5 (d, J = 8.2 Hz, 2H), 7.1 (d, J = 8.0 Hz,
2H), 6.8 (s, 1H), 4.5 (br s, 1H), 4.0 (br s, 1H), 3.2 (m, 2H), 2.3 (s, 3H), 1.3 (s, 9H),
1.2 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 185.0, 161.1, 155.0, 154.4,
138.3, 129.5, 126.8, 126.0, 124.0, 101.7, 79.5, 46.0, 33.5, 28.3, 21.0, 19.0; HRMS
(BioTOF II ESI) m/z calcd for C20H25NNaO4 [M+Na]+ 366.1676; found 366.1677.
tert-Butyl 1-(3-Formyl-5-(4-methoxyphenyl)furan-2-yl)propan-2-ylcarbamate
(32b).
NH
O
O
Boc
OMe
Rf 0.41 (1:6 EtOAc/hexanes); a yellow oil, 1H NMR (400 MHz, CDCl3): δ 9.9 (s,
1H), 7.6 (d, J = 9.6 Hz, 2H), 7.3 (d, J = 9.6 Hz, 2H), 6.7 (s, 1H), 4.8 (d, J = 8.0 Hz,
1H), 4.1 (br s, 1H), 3.8 (s, 3H), 3.2-3.1 (m, 2H), 1.4 (s, 9H), 1.2 (d, J = 6.8 Hz, 3H) ;
13C NMR (100 MHz, CDCl3): δ 185.0, 161.1, 155.1, 154.1, 144.8, 133.0, 126.0,
53
125.5, 114.2, 100.6, 79.3, 55.2, 41.7, 33.5, 28.5, 20.2; HRMS (BioTOF II ESI) m/z
calcd for C20H25NNaO5 [M+Na]+ 382.1630; found 382.1636.
tert-Butyl 1-(5-(4-Chlorophenyl)-3-formylfuran-2-yl)propan-2-ylcarbamate
(32c).
NH
O
O
Boc
Cl
Rf 0.44 (1:3 EtOAc/hexanes), a brown oil; 1H NMR (400 MHz, CDCl3): δ 9.8 (s, 1H),
7.5 (d, J = 8.5 Hz, 2H), 7.3 (d, J = 8.5 Hz, 2H), 6.8 (s, 1H), 4.6 (t, J = 6.3 Hz, 1H),
4.5(br s, 1H), 3.1 (m, 2H), 1.5 (s, 9H), 1.2 (d, J = Hz, 3H); 13C NMR (100 MHz,
CDCl3): δ 185.0, 161.8, 155.8, 153.2, 134.1, 132.9, 129.1, 128.0, 125.4, 103.0, 79.8,
46.0, 41.8, 28.1, 17.0; HRMS (BioTOF II ESI) m/z calcd for C19H22NaClNO4
[M+Na]+ 386.1135; found 386.1100.
General method of the Syntheses of tert-Butyl 2-(3-Formyl-5-arylfuran-2-
yl)propan-2-ylcarbamate (33-33c).
tert-Butyl 5-arylethynyl-4-oxo-2-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (28-
28c) (100 mg, 0.248-0.268 mmol) was dissolved in dry CH2Cl2 under N2 at room
temperature and stirred for 10 min. Then AuCl3 (15 µL, 0.2 M in CH3CN) solution
was added in one portion and MeOH (14.9 mL, 0.368 mmol) was added. The
resulting reaction mixture stirred until all starting material was consumed unless
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otherwise specified. The solvent was removed under reduced pressure. The crude
mixture was purified by silica gel column chromatography (1: 4 EtOAc/ hexanes).
tert-Butyl 2-(3-Formyl-5-phenylfuran-2-yl)-1-phenylethylcarbamate (33).
NH
O
O
Boc
Ph
24 mg (23%), a yellow powder, mp 118-120 °C; 1H NMR (400 MHz, CDCl3): δ 9.6
(s, 1H), 7.5-7.2 (m, 10H), 6.8 (s, 1H), 5.1 (m, 2H), 3.5 (m, 2H), 1.3 (s, 9H); 13C NMR
(100 MHz, CDCl3): δ 184.9, 155.0, 154.2, 132.0, 129.4, 128.8, 128.5, 128.3, 126.9,
126.1, 125.8, 124.1, 102.7, 83.7, 80.0, 54.4, 34.6, 28.3.
tert-Butyl 2-(3-Formyl-5-p-tolylfuran-2-yl)-1-phenylethylcarbamate (33a).
NH
O
O
Boc
Ph
50 mg (48%), a yellow powder, mp 150 -151 °C; 1H NMR (400 MHz, CDCl3): δ 9.6
(s, 1H), 7.4-7.2 (m, 9H), 6.7 (s, 1H), 5.1 (br s, 2H), 3.5 (m, 2H), 2.3 (s, 3H), 1.3 (s,
9H); 13C NMR (100 MHz, CDCl3): δ 185.0, 159.7, 155.0, 154.4, 140.6, 138.3, 129.5,
128.8, 127.9, 126.7, 126.1, 125.8, 124.0, 101.8, 79.9, 54.4, 34.6, 28.3, 21.3; HRMS
(BioTOF II ESI) m/z calcd for C25H27NNaO4 [M+Na]+ 428.1835; found 428.1815.
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tert-Butyl 2-(3-Formyl-5-(4-methoxyphenyl)furan-2-yl)-1-phenylethylcarbamate
(33b).
NH
O
O
Boc
OMe
Ph
80 mg (77%, 15 mg of starting material recovered.), a yellow powder, mp 140-141
°C; 1H NMR (400 MHz, CDCl3): δ 9.5 (s, 1H), 7.5-6.8 (m, 9H), 6.6 (s, 1H), 5.1 (br s,
2H), 3.8 (s, 3H), 3.5-3.5 (m, 2H), 1.3 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 185.0,
159.7, 155.0, 154.3, 128.8, 128.2, 127.9, 126.1, 125.8, 125.6, 122.4, 114.2, 114.0,
101.0, 79.9, 55.4, 54.3, 34.6, 28.3; HRMS (BioTOF II ESI) m/z  calcd for
C25H27NNaO5 [M+Na]+ 444.1781; found 444.1774.
tert-Butyl 2-(5-(4-Chlorophenyl)-3-formylfuran-2-yl)-1-phenylethylcarbamate
(33c).
NH
O
O
Boc
Cl
Ph
38 mg (36%), a yellow powder, mp 152-154 °C; 1H NMR (400 MHz, CDCl3): δ 9.6
(s, 1H), 7.5-7.2 (m, 9H), 6.8 (s, 1H), 5.1 (br s, 2H), 3.5-3.4 (m, 2H), 1.43(s, 9H); 13C
NMR (100 MHz, CDCl3): δ 185.0, 155.0, 153.1, 134.1, 132.7, 129.0, 128.9, 128.5,
128.0, 126.2, 125.8, 125.6, 125.3, 103.1, 80.0, 54.4, 34.6, 28.3; HRMS (BioTOF II
ESI) m/z calcd for C24H24ClNNaO4 [M+Na]+ 448.1286; found 448.1270.
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General method of the Syntheses of tert-Butyl 1-(3-Formyl-5-arylfuran-2-yl)-3-
phenylpropan-2-ylcarbamate (34-34c).
tert-Butyl 5-arylethynyl-4-oxo-2-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (29-
29c) (100 mg, 0.237-0.258 mmol) was dissolved in dry CH2Cl2 under N2 at room
temperature and stirred for 10 min. Then AuCl3(12 µL, 0.2 M in CH3CN) solution
was added in one portion and MeOH (15.7 mL, 0.387 mmol) was added. The
resulting reaction mixture was stirred for 1 h, or 2 h in case of 34b and 34c. The
solvent was removed under reduced pressure. The crude mixture was purified by
CombiFlash chromatography (1: 4 EtOAc/ hexanes).
tert-Butyl 1-(3-Formyl-5-phenylfuran-2-yl)-3-phenylpropan-2-ylcarbamate (34).
NH
O
O
Boc
Bn
66 mg (63%), a white powder, mp 146-148 °C; 1H NMR (400 MHz, CDCl3): δ 9.8 (s,
1H), 7.5-7.1 (m, 10H), 6.8 (s, 1H), 4.6 (d, J = 7.9 Hz, 1H), 4.2 (d, J = 6.4 Hz, 1H), 3.2
(m, 2H), 2.8 (m, 2H), 1.3 (s, 9H); 13C NMR (100 MHz, CDCl3): δ  185.1, 161.3,
155.1, 154.2, 137.3, 129.5, 129.3, 128.8, 128.7, 128.3, 127.3, 126.8, 124.1, 102.6,
79.7, 51.3, 40.4, 31.1, 28.3; HRMS (BioTOF II ESI) m/z calcd for C25H27NNaO4
[M+Na]+ 428.1838; found 428.1832.
tert-Butyl 1-(3-Formyl-5-p-tolylfuran-2-yl)-3-phenylpropan-2-ylcarbamate (34a).
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NH
O
O
Boc
Bn
74 mg (71%), a yellow powder, mp 114-116 °C; 1H NMR (400 MHz, CDCl3): δ 9.8
(s, 1H), 7.5-7.1 (m, 9H), 6.8 (s, 1H), 4.6 (d, J = 7.6 Hz, 1H), 4.2 (d, J = 6.5 Hz, 1H),
3.2-3.1 (m, 2H), 2.9-2.8(m, 2H), 2.3 (s, 3H), 1.3 (s, 9H); 13C NMR (100 MHz,
CDCl3): δ 184.9, 155.0, 154.2, 132.0, 129.4, 129.1, 128.8, 128.3, 127.9, 126.9, 126.1,
125.8, 124.1, 102.7, 80.0, 57.7, 54.4, 34.6, 28.3, 27.9; HRMS (BioTOF II ESI) m/z
calcd for C26H29NNaO4 [M+Na]+442.1994; found 442.1989.
tert-Butyl 1-(3-Formyl-5-(4-methoxyphenyl)furan-2-yl)-3-phenylpropan-2-
ylcarbamate (34b).
NH
O
O
Boc
OMe
Bn
81 mg (77%), a yellow powder, mp 155-156 °C; 1H NMR (400 MHz, CDCl3): δ 9.7
(s, 1H), 7.5-6.8 (m, 9H), 6.7 (s, 1H), 4.6 (d, J = 7.8 Hz, 1H), 4.2 (m, 1H), 3.7 (s, 3H),
3.6-3.1 (m, 2H), 3.1-2.8 (m, 2H), 1.3 (s, 9H); 13C NMR (100 MHz, CDCl3): δ
185.1,160.7, 159.7, 155.1, 154.3, 137.4, 129.3, 128.7, 126.8, 126.1, 125.6, 122.4,
114.3, 100.8, 79.7, 55.4, 51.2, 40.4, 31.0, 28.3; HRMS (BioTOF II ESI) m/z calcd for
C26H29NNaO5 [M+Na]+458.1938; found 458.1937.
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tert-Butyl 1-(5-(4-Chlorophenyl)-3-formylfuran-2-yl)-3-phenylpropan-2-
ylcarbamate (34c).
NH
O
O
Boc
Cl
Bn
45 mg (43%), a white powder, mp 182 °C; 1H NMR (400 MHz, CDCl3): δ 9.8 (s,
1H), 7.3-7.2 (m, 9H), 6.8 (s, 1H), 4.6 (d, J = 7.9 Hz, 1H), 4.2 (m, 1H), 3.2-3.1 (m,
2H), 2.9-2.8 (m, 2H), 1.3 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 184.9, 161.4,
155.1, 153.1, 137.2, 134.1, 129.3, 129.1, 128.7, 127.9, 126.9, 126.1, 125.3, 103.1,
79.7, 51.2, 40.5, 31.3, 27.9; HRMS (BioTOF II ESI) m/z calcd for C25H26ClNNaO4
[M+Na]+ 462.1448; found 462.1404.
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